PN summer web series kicks off in July! Learn more

DARA BioSciences Receives Fast Track Designation from FDA for Treatment of Chemotherapy-Induced Neuropathic Pain in Patients with Cancer

In a program designed to facilitate the development and expedite the review of new drugs, the FDA created the Fast Track program. DARA BioSciences has been awarded the Fast Track designation for their KRN5500 investigational drug which will be used for the treatment of neuropathic pain in cancer patients. DARA earlier reported positive results from its Phase II clinical trial. Amy Abernethy, MD, Director of Duke Cancer Care Research Program said, “….Patients with chemotherapy-indeced PN are distressing to treat….they have long lives ahead of them, but severe pain problems. …I think KRN5500 holds promise as a potential help.” READ MORE

Source: Globe Newswire